PT2922576T - Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática - Google Patents

Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática

Info

Publication number
PT2922576T
PT2922576T PT138574553T PT13857455T PT2922576T PT 2922576 T PT2922576 T PT 2922576T PT 138574553 T PT138574553 T PT 138574553T PT 13857455 T PT13857455 T PT 13857455T PT 2922576 T PT2922576 T PT 2922576T
Authority
PT
Portugal
Prior art keywords
drugs
administration
evaluation
nitrogen
treatment
Prior art date
Application number
PT138574553T
Other languages
English (en)
Inventor
Scharschmidt Bruce
Mokhtarani Masoud
Original Assignee
Horizon Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Therapeutics Llc filed Critical Horizon Therapeutics Llc
Publication of PT2922576T publication Critical patent/PT2922576T/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
PT138574553T 2012-11-21 2013-11-21 Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática PT2922576T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728967P 2012-11-21 2012-11-21
US201361759292P 2013-01-31 2013-01-31

Publications (1)

Publication Number Publication Date
PT2922576T true PT2922576T (pt) 2018-01-24

Family

ID=50728524

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138574553T PT2922576T (pt) 2012-11-21 2013-11-21 Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática

Country Status (21)

Country Link
US (3) US9289406B2 (pt)
EP (2) EP2922576B1 (pt)
JP (1) JP2016506378A (pt)
KR (1) KR20150086510A (pt)
CN (1) CN104797272A (pt)
AU (1) AU2013347905B2 (pt)
BR (1) BR112015011778A2 (pt)
CA (1) CA2891657A1 (pt)
CY (1) CY1120163T1 (pt)
DK (1) DK2922576T3 (pt)
ES (1) ES2654774T3 (pt)
HK (1) HK1210699A1 (pt)
HR (1) HRP20180041T1 (pt)
HU (1) HUE036133T2 (pt)
LT (1) LT2922576T (pt)
PL (1) PL2922576T3 (pt)
PT (1) PT2922576T (pt)
RS (1) RS56757B1 (pt)
SI (1) SI2922576T1 (pt)
SM (1) SMT201800022T1 (pt)
WO (1) WO2014081977A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2757373C (en) 2009-04-03 2018-05-08 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
EA201691430A1 (ru) 2009-06-08 2017-02-28 ЮСиЭл БИЗНЕС ПиЭлСи Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата
DK2760479T3 (en) 2011-09-30 2017-07-17 Horizon Therapeutics Llc Nitrogen-removing drug for use in a method of treating a nitrogen retention disorder
ES2623470T3 (es) 2012-04-20 2017-07-11 Horizon Therapeutics, Llc HPN-100 para uso en el tratamiento de trastornos de retención de nitrógeno
EP2922576B1 (en) * 2012-11-21 2017-11-08 Horizon Therapeutics, LLC Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
US10039735B2 (en) * 2014-11-24 2018-08-07 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
WO2018208677A1 (en) 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Processes of making l-ornithine phenylacetate
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
EP4210709B1 (en) 2020-09-14 2025-10-29 Pharma Cinq, LLC 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position
BR112023010517A2 (pt) * 2020-12-01 2024-02-06 Wellstat Therapeutics Corp 5'-o-fenilacetil uridina e seu uso terapêutico

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
ES2157422T3 (es) 1995-02-07 2001-08-16 Brusilow Entpr Llc Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos.
US6219567B1 (en) 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
CN1778963A (zh) * 2004-11-23 2006-05-31 苏州艾杰生物科技有限公司 血氨含量测定方法及血氨诊断试剂盒
SG158073A1 (en) 2004-11-26 2010-01-29 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
WO2007059031A2 (en) 2005-11-10 2007-05-24 Massachusetts Institute Of Technology Methods and compositions for raising levels and release of gamma aminobutyric acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
CN101959429B (zh) 2008-01-08 2014-09-10 阿克塞利亚制药公司 抗微生物肽系统的激动剂
PL3133396T3 (pl) 2008-04-29 2019-03-29 Horizon Therapeutics, Llc Sposób leczenia z zastosowaniem leków wychwytujących amoniak
US20120022157A1 (en) 2008-08-29 2012-01-26 Ucyclyd Pharma, Inc Dosing and monitoring patients on nitrogen-scavenging drugs
PT3133396T (pt) * 2008-08-29 2018-12-07 Immedica Pharma Ab Métodos de tratamento utilizando fármacos eliminadores de amoníaco
EP2954780A1 (en) 2009-07-24 2015-12-16 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
US20130224277A1 (en) 2010-08-31 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation
DK2760479T3 (en) * 2011-09-30 2017-07-17 Horizon Therapeutics Llc Nitrogen-removing drug for use in a method of treating a nitrogen retention disorder
ES2623470T3 (es) * 2012-04-20 2017-07-11 Horizon Therapeutics, Llc HPN-100 para uso en el tratamiento de trastornos de retención de nitrógeno
EP2922576B1 (en) * 2012-11-21 2017-11-08 Horizon Therapeutics, LLC Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
EP3019074B1 (en) 2013-09-30 2018-08-29 Horizon Therapeutics, LLC Diagnosing, grading, monitoring, and treating hepatic encephalopathy
EP2986325B1 (en) 2013-10-14 2019-06-26 Immedica Pharma AB Methods of treating urea cycle disorders

Also Published As

Publication number Publication date
WO2014081977A1 (en) 2014-05-30
CN104797272A (zh) 2015-07-22
JP2016506378A (ja) 2016-03-03
LT2922576T (lt) 2018-02-12
EP2922576A4 (en) 2016-05-04
BR112015011778A2 (pt) 2017-07-11
DK2922576T3 (en) 2018-01-15
HK1213778A1 (en) 2016-07-15
US20180017546A1 (en) 2018-01-18
PL2922576T3 (pl) 2018-08-31
HK1210699A1 (en) 2016-05-06
CA2891657A1 (en) 2014-05-30
US20160223520A1 (en) 2016-08-04
SI2922576T1 (en) 2018-04-30
AU2013347905B2 (en) 2018-10-04
RS56757B1 (sr) 2018-04-30
US9289406B2 (en) 2016-03-22
US20140142186A1 (en) 2014-05-22
EP2922576A1 (en) 2015-09-30
HRP20180041T1 (hr) 2018-06-01
SMT201800022T1 (it) 2018-03-08
HUE036133T2 (hu) 2018-06-28
KR20150086510A (ko) 2015-07-28
AU2013347905A1 (en) 2015-04-30
EP2922576B1 (en) 2017-11-08
CY1120163T1 (el) 2018-12-12
EP3335735A1 (en) 2018-06-20
ES2654774T3 (es) 2018-02-15

Similar Documents

Publication Publication Date Title
CY1125560T1 (el) Πολυκυκλικες ενωσεις καρβαμοϋλπυριδονης και φαρμακευτικη χρηση αυτων
PT2922576T (pt) Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática
HRP20181364T1 (hr) Aminotriazolopiridin, namijenjen upotrebi u liječenju upale, te njegovi farmacetski pripravci
EP2922877A4 (en) IMPROVED PEPTIDATE MEDICINES
HRP20260139T1 (hr) Farmaceutski pripravak, postupci za liječenje i njegove uporabe
BR112015000437A2 (pt) imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
DK3639872T3 (da) Lægemiddeladministrationsanordning
BR112015000529A2 (pt) métodos e sistemas de entrega de fármaco de pó seco
PT2968172T (pt) Formulação estabilizada de vitamina d de liberação modificada e método de administração da mesma
BR112013033072A2 (pt) agente para indução de apoptose e composição farmacêutica
CO7020897A2 (es) Dispositivo de inhalación para fármacos en polvo
PT2872497T (pt) Derivados de cromanilo para o tratamento de doenças mitocondriais
PL2842945T3 (pl) Pochodna sulfonamidowa i jej zastosowanie medyczne
EP2804599A4 (en) PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
PT2968368T (pt) Administração craniana de substâncias farmacêuticas
IL262252B (en) Therapeutic compositions and methods involving mrna transfection
DK3357522T3 (da) Coatet medicinsk genstand til lægemiddelsfrigivelse
DK3079655T3 (da) Inhalerbare lægemidler
SG11201507305SA (en) Pharmaceutical combination drug
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
PT3054926T (pt) Formulação de atazanavir e cobicistat para tratamento de hiv
BR112015033065A8 (pt) nanopartícula de lipídio; composição farmacêutica; e uso da nanopartícula de lipídio
DK2897588T3 (da) Inhalerbart lægemiddel
BR112014017217A8 (pt) agente e composição farmacêutica